AU2014339984B2 - Stable, aqueous antibody formulations - Google Patents

Stable, aqueous antibody formulations Download PDF

Info

Publication number
AU2014339984B2
AU2014339984B2 AU2014339984A AU2014339984A AU2014339984B2 AU 2014339984 B2 AU2014339984 B2 AU 2014339984B2 AU 2014339984 A AU2014339984 A AU 2014339984A AU 2014339984 A AU2014339984 A AU 2014339984A AU 2014339984 B2 AU2014339984 B2 AU 2014339984B2
Authority
AU
Australia
Prior art keywords
antibody
formulation
chain variable
variable region
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014339984A
Other languages
English (en)
Other versions
AU2014339984A1 (en
Inventor
William Leach
Rachael LEWUS
James MCGIVNEY
Kelcy NEWELL
Kevin Douglas Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2014339984A1 publication Critical patent/AU2014339984A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: MEDIMMUNE, LLC
Application granted granted Critical
Publication of AU2014339984B2 publication Critical patent/AU2014339984B2/en
Priority to AU2020204608A priority Critical patent/AU2020204608A1/en
Priority to AU2022291595A priority patent/AU2022291595B2/en
Priority to AU2025230794A priority patent/AU2025230794A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AU2014339984A 2013-10-24 2014-10-23 Stable, aqueous antibody formulations Active AU2014339984B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020204608A AU2020204608A1 (en) 2013-10-24 2020-07-09 Stable, aqueous antibody formulations
AU2022291595A AU2022291595B2 (en) 2013-10-24 2022-12-23 Stable, aqueous antibody formulations
AU2025230794A AU2025230794A1 (en) 2013-10-24 2025-09-12 Stable, aqueous antibody formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895143P 2013-10-24 2013-10-24
US61/895,143 2013-10-24
PCT/US2014/061997 WO2015061584A1 (en) 2013-10-24 2014-10-23 Stable, aqueous antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204608A Division AU2020204608A1 (en) 2013-10-24 2020-07-09 Stable, aqueous antibody formulations

Publications (2)

Publication Number Publication Date
AU2014339984A1 AU2014339984A1 (en) 2016-04-28
AU2014339984B2 true AU2014339984B2 (en) 2020-04-09

Family

ID=52993565

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014339984A Active AU2014339984B2 (en) 2013-10-24 2014-10-23 Stable, aqueous antibody formulations
AU2020204608A Abandoned AU2020204608A1 (en) 2013-10-24 2020-07-09 Stable, aqueous antibody formulations
AU2022291595A Active AU2022291595B2 (en) 2013-10-24 2022-12-23 Stable, aqueous antibody formulations
AU2025230794A Pending AU2025230794A1 (en) 2013-10-24 2025-09-12 Stable, aqueous antibody formulations

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020204608A Abandoned AU2020204608A1 (en) 2013-10-24 2020-07-09 Stable, aqueous antibody formulations
AU2022291595A Active AU2022291595B2 (en) 2013-10-24 2022-12-23 Stable, aqueous antibody formulations
AU2025230794A Pending AU2025230794A1 (en) 2013-10-24 2025-09-12 Stable, aqueous antibody formulations

Country Status (23)

Country Link
US (4) US20150118249A1 (enExample)
EP (2) EP3060229B1 (enExample)
JP (3) JP6483673B2 (enExample)
KR (3) KR102238065B1 (enExample)
CN (4) CN112107538A (enExample)
AU (4) AU2014339984B2 (enExample)
BR (1) BR112016008576B1 (enExample)
CA (1) CA2926089C (enExample)
CY (1) CY1125697T1 (enExample)
DK (1) DK3060229T3 (enExample)
ES (1) ES2893861T3 (enExample)
HR (1) HRP20211371T1 (enExample)
HU (1) HUE055919T2 (enExample)
LT (1) LT3060229T (enExample)
MX (2) MX388893B (enExample)
PL (1) PL3060229T3 (enExample)
PT (1) PT3060229T (enExample)
RS (1) RS62419B1 (enExample)
RU (1) RU2763787C2 (enExample)
SG (2) SG11201603206UA (enExample)
SI (1) SI3060229T1 (enExample)
SM (1) SMT202100580T1 (enExample)
WO (1) WO2015061584A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CA2870149A1 (en) * 2012-05-03 2013-11-07 Medimmune, Llc Method for analyzing sample components
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
LT3060229T (lt) * 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
US12065482B2 (en) 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
ES3064802T3 (en) * 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
CN111024963A (zh) * 2019-12-27 2020-04-17 桂林英美特生物技术研究所 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂
US20230115267A1 (en) * 2020-03-13 2023-04-13 Samsung Bioepis Co., Ltd. Pharmaceutical liquid composition having increased stability
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业（上海）股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗ｉｌ５ｒ抗体製剤
DE212025000115U1 (de) * 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20070048304A1 (en) * 1995-09-11 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. Method of treating allergy using antibody against human interleukin-5 receptor alpha chain
US20090304706A1 (en) * 2006-04-21 2009-12-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20100074903A1 (en) * 2008-09-19 2010-03-25 Ulla Grauschopf Novel antibody formulation
WO2013059408A1 (en) * 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
US20130109807A1 (en) * 2011-10-26 2013-05-02 Bio-Rad Laboratories, Inc. Removal of virucidal agents in mixed mode chromatography

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
BRPI0410658B8 (pt) * 2003-05-26 2021-06-22 In Baik Woo seringa descartável
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE202006001995U1 (de) * 2006-02-07 2006-06-08 Sarstedt Ag & Co. Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
CN104039352A (zh) * 2011-11-01 2014-09-10 米迪缪尼有限公司 用于降低哮喘急性恶化的频率和严重性的方法
AR090244A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
SMT201900311T1 (it) * 2013-08-12 2019-07-11 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
CA2918105C (en) 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
BR112016002462A8 (pt) 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe
LT3060229T (lt) * 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20070048304A1 (en) * 1995-09-11 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. Method of treating allergy using antibody against human interleukin-5 receptor alpha chain
US20090304706A1 (en) * 2006-04-21 2009-12-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20100074903A1 (en) * 2008-09-19 2010-03-25 Ulla Grauschopf Novel antibody formulation
WO2013059408A1 (en) * 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
US20130109807A1 (en) * 2011-10-26 2013-05-02 Bio-Rad Laboratories, Inc. Removal of virucidal agents in mixed mode chromatography

Also Published As

Publication number Publication date
JP2019116480A (ja) 2019-07-18
DK3060229T3 (da) 2021-10-11
AU2022291595A1 (en) 2023-03-16
CN105611938B (zh) 2024-12-31
JP6483673B2 (ja) 2019-03-13
RU2016119755A (ru) 2017-11-27
MX2021015825A (es) 2022-02-03
SMT202100580T1 (it) 2021-11-12
WO2015061584A1 (en) 2015-04-30
RU2021137159A (ru) 2022-01-11
LT3060229T (lt) 2021-09-27
KR102238065B1 (ko) 2021-04-07
KR102109053B1 (ko) 2020-05-13
AU2020204608A1 (en) 2020-07-30
CA2926089C (en) 2022-08-30
CN119971024A (zh) 2025-05-13
RU2016119755A3 (enExample) 2018-04-28
US20150118249A1 (en) 2015-04-30
BR112016008576B1 (pt) 2023-03-07
US12582716B2 (en) 2026-03-24
SI3060229T1 (sl) 2021-11-30
ES2893861T3 (es) 2022-02-10
EP3060229A4 (en) 2017-08-16
MX388893B (es) 2025-03-20
EP3892288A1 (en) 2021-10-13
KR20160068946A (ko) 2016-06-15
AU2025230794A1 (en) 2025-10-02
SG10201803178UA (en) 2018-05-30
EP3060229B1 (en) 2021-08-25
JP2016535020A (ja) 2016-11-10
AU2014339984A1 (en) 2016-04-28
US20250170245A1 (en) 2025-05-29
KR20210041101A (ko) 2021-04-14
JP6896781B2 (ja) 2021-06-30
US20200297855A1 (en) 2020-09-24
CA2926089A1 (en) 2015-04-30
CN113350278A (zh) 2021-09-07
EP3060229A1 (en) 2016-08-31
RS62419B1 (sr) 2021-10-29
CN113350278B (zh) 2023-03-24
KR20200051844A (ko) 2020-05-13
MX2016004605A (es) 2016-11-14
PL3060229T3 (pl) 2021-12-27
BR112016008576A2 (pt) 2017-10-03
CN105611938A (zh) 2016-05-25
CN112107538A (zh) 2020-12-22
HK1221900A1 (zh) 2017-06-16
JP2021152034A (ja) 2021-09-30
HUE055919T2 (hu) 2022-01-28
PT3060229T (pt) 2021-10-07
SG11201603206UA (en) 2016-05-30
US20190201535A1 (en) 2019-07-04
CY1125697T1 (el) 2024-02-16
HRP20211371T1 (hr) 2021-11-26
RU2763787C2 (ru) 2022-01-11
AU2022291595B2 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
AU2022291595B2 (en) Stable, aqueous antibody formulations
US20150239970A1 (en) Stable, Low Viscosity Antibody Formulation
HK40060962A (en) Stable, aqueous antibody formulations
HK40061789A (en) Stable, aqueous antibody formulations
HK1227741B (en) Stable, aqueous antibody formulations
HK40061789B (en) Stable, aqueous antibody formulations
HK40126992A (en) Stable, aqueous antibody formulations
HK40042589A (en) Stable, aqueous antibody formulations
HK1221900B (en) Stable, aqueous antibody formulations
EP3808777A1 (en) Stable liquid antibody formulations

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): MEDIMMUNE, LLC

FGA Letters patent sealed or granted (standard patent)